Introduction
Many tumors can present peptide antigens in the context of major histocompatibility complex (MHC) to T cells receptor but few primary murine or human neoplastic cells express costimulatory molecules necessary to induce generation of anti-tumor-specific cytotoxic T cells. [1] [2] [3] [4] Antigen presentation in the absence of costimulation is likely to induce anergy 4 and may allow tumor cells to escape from immune recognition. Enhancement of antigen-presenting cell (APC) capacity of acute lymphoblastic leukemia (ALL) cells can be developed into a strategy for a vaccine therapy. Irradiated B cell precursor (BCP)-ALL cells, rendered capable of presenting antigens, could be able to induce a host anti-leukemia immune response when administered to patients with minimal residual disease. It has been shown that ALL cells are inefficient allogeneic APC and that CD40 cross-linking on ALL cells by soluble trimeric CD40 ligand (stCD40L) can induce expression of B7 family members and convert non-immunogenic ALL cells into competent APC, able to induce alloantigen-specific T cells proliferation 4 and generation of autologous anti-ALL specific cytotoxic T cell lines from the bone marrow (BM) of ALL patients collected at diagnosis. [5] [6] [7] More recently, generation of autologous anti-ALL-specific cytotoxic T cells have been obtained from post-remission peripheral blood (PB) of ALL patients. 8 In an effort to enhance the APC capacity of ALL cells, we used cultures in which BCP-ALL cell viability was supported by human bone marrow stroma (HBMS) and then tested the effect of a stCD40L molecule. Our findings show that allogeneic T cells responsiveness to BCP-ALL cells can be induced by the simple contact with stroma and that stCD40L acts in concert with it to improve leukemic cells APC capacity. Furthermore, stCD40L-stimulated BCP-ALL cells elicit IFN-␥ production by rare residual autologous BM T cells at diagnosis, thus providing an easy assay to measure the frequency of leukemia-specific autologous T cells.
Materials and methods

Cells
BM cells were collected from 23 children with BCP-ALL at diagnosis.The main clinical and laboratory features are described in Table 1 . In all cases more than 80% of blast infiltration was present and more than 90% of the blasts expressed CD19 antigen and lacked surface Ig (sIg). Samples for HBMS cultures were taken from healthy transplantation donors, normal PB samples were from healthy volunteers. Mononuclear cells (MNC), either from BM and PB samples, were obtained after centrifugation on a density gradient using FicollHyPaque (Pharmacia, Uppsala, Sweden) and washed three times in phosphate-buffered saline (PBS). T cells used for allogeneic proliferation were separated from MNC by further centrifugation on Percoll gradient as previously described. 9 Dendritic cells (DC) used in allogeneic mixed lymphocyte reaction (MLR) experiments were obtained from PB monocytes cultured for 7 days in modified RPMI-1640 (Gibco BRL, Grand Island, NY, USA) in the presence of 50 ng/ml of GM-CSF and 20 ng/ml of IL-13 as previously described. 10 All leukemic samples were cryopreserved in RPMI-1640 culture medium supplemented with 50% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT, USA) and 10% dimethylsulfoxide (DMSO; Merck, Darmstadt, Germany). Vials were first stored at −80°C for 24 h and then stored in liquid nitrogen. Thawed leukemic cells were used for the experiments. The institutional review board approved this study and informed consent was obtained from patients and their guardians. 
HBMS cultures
HBMS layers were prepared as previously described. 11 Briefly, BM MNC were resuspended in RPMI-1640 that contained 10% FBS, 10 −6 mol/l hydrocortisone (Sigma Chemicals, St Louis, MO, USA), 2 mmol/l L-glutamine, and penicillin-streptomycin. Cells were incubated at 33°C in 5% CO 2 and 90% humidity, and were fed every 7 days by replacing 50% of the supernatant with identical fresh medium. After formation of confluent layers, cells were detached by treatment with trypsin (BioWhittaker,Walkersville, MD, USA), washed once in RPMI-1640 with 10% FBS, and resuspended in fresh RPMI-1640 medium containing FBS, hydrocortisone, L-glutamine, and antibiotics. Cells were distributed into 24-well flat-bottom plates and cultured until a confluent stromal layer was seen.
BCP-ALL cell culture on HBMS layers
Before initiating the experiments, the medium of HBMS culture was removed and adherent cells were washed twice with PBS. Leukemic cells were resunspended in AIM-V medium (Gibco BRL) at a final concentration of 3 × 10 6 /ml. One milliliter of the sunspension was seeded on to each 24-well tissue culture plate containing HBMS cells. For CD40 cross-linking, a stCD40L molecule (CD40 Ligand kit; Alexis Corporation, Lausen, Switzerland) was added to the AIM-V medium at a final concentration of 0.5 g/ml and cells were incubated at 37°C in 5% CO 2 and 90% humidity. After 48 h of culture, cells were detached by treatment with trypsin, washed once in RPMI-1640 containing FBS and passed through a 19-gauge Leukemia needle to disrupt clumps. After a second wash, cells were used for phenotypic analysis, immunomagnetic cell sorting and functional studies.
Immunomagnetic cell sorting
T cells from seven thawed leukemic BM samples were isolated by incubating 10 8 mononuclear cells in 300 l of PBS with 100 l of Fc receptor blocking reagent, 100 l of anti-CD4 and 100 l of anti-CD8-conjugated magnetic beads reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) followed by incubation for 30 min at 4-8°C. After washing with PBS, cells were processed through a MS+ separation column (Miltenyi Biotec), placed in a magnetic field, and labeled cells were retained. For higher purity, a second run with a new column was applied to the recovered fraction. To purify leukemic cells from contaminating stromal cells after stCD40L stimulation, 
Allogeneic T cells proliferation assay
Purified stCD40L-stimulated ALL cells (1 × 10 5 ) were co-cultured with allogeneic lymphocytes (2 × 10 5 ) in a 96-well Ubottomed plate for 4 days at 37°C in RPMI-1640 supplemented with 5% heat-inactivated human AB serum (Sigma Chemicals). Cells were pulsed with 1 Ci of 3 H-thymidine (Amersham Pharmacia Biotech, NJ, USA) for the last 18 h of the culture period, and then harvested on to glass fiber filters. 3 H-thymidine incorporation was measured by liquid scintillation spectrophotometry.
ELISPOT assay
For the quantitative detection of IFN-␥ producing cells, the human interferon-␥ kit (Mabtech, Nacka, Sweden) was used according to the manufacturer's instructions. Briefly, polyvinylidene difluoride (PVDF)-backed 96-well plates (Millipore, Walkersville, MD USA) were coated with antihuman IFN-␥ antibody (Mabtech) overnight. The wells were then washed with 200 l of PBS for six times. Fifty thousand T cells or 0.5 × 10 5 BCP-ALL cells were cultured either alone or together, in a 1:1 ratio, in each well. After 24 h incubation at 37°C, 90% humidity, 5% CO 2 , cells were washed with 200 l PBS six times, and incubated with biotinylated mouse antihuman IFN-␥ antibody for 2 h at room temperature. After an additional six washes with PBS, streptoavidine-alkaline phosphatase (Biorad, Hercules, CA, USA) was added and incubated for 1 h at room temperature. After another washing step with PBS, 100 l/well of BCIP/NBT substrate (containing nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate in acqueous dimethylformamide, Biorad) was added for 25 min. Color development was stopped by washing under running water. After drying at room temperature, spots were enumerated using the AlphaImager system (Alpha Innotech, San Leandro, CA, USA) which incorporates a CCD camera and a computer imaging software. To assess the sensitivity, in our hands, of the IFN-␥ ELISPOT assay, we used MNC isolated from PB of HLA-A2.01 healthy donors with a recent (Ͻ6 months) positive anamnesis for influenza virus infection.
Restimulation of memory T cells, specific for influenza matrix epitope, was performed by incubating fresh MNC with M1 5866 FLU peptide (GILGFVFTL; Primm srl, Milan, Italy) at the concentration of 5 M for 12 h. At the end of the incubation time and before starting the ELISPOT incubation, monocytes were eliminated by immunomagnetic positive selection using anti-CD14-conjugated magnetic beads (Miltenyi) as described above.
Statistical analysis
The statistical significance between the treatment groups was determined using the paired t-test for matched pairs and the significance level was set at 10%.
Results
stCD40L and HBMS induce modulation of costimulatory, MHC and adhesion molecules on BCP-ALL cells; stCD40L is essential to induce expression of CD80
BCP-ALL cells, from 23 patients at diagnosis, were cultured, after thawing, on HBMS in the presence of 0.5 g/ml of stCD40L for 48 h, collected and phenotypically characterized. HBMS maintained leukemic cell viability in all cases (mean cell viability Ͼ85%). Under these conditions we observed upregulation (in terms of % of positive cells) or de novo expression of CD40 in 22/22 cases and of costimulatory molecules CD80 and CD86 in 15/23 and 21/23 cases, respectively, as shown in Table 2 and in Figure 1 for two representative cases. HBMS alone, although to a lesser extent, was able to induce modulation of CD40 and CD86 molecules, but not CD80, in a similar proportion of cases (Table 2 and Figure 1 ). The effect of stCD40L on CD40 and CD86 expression was additive with that of HBMS as demonstrated by the significant difference in the proportion of cells expressing CD40 and CD86 (P value = 0.0122 and 0.0474, respectively), after culture on HBMS with or without stCD40L ( Table 2) (Figure 2 ). We then studied surface expression of CD34 and CD10 in the same culture conditions. We did not observe variations either in the proportion of CD34 and CD10 expressing cells (data not shown) or in the MFI values for both molecules (Figure 2 ). The effect of stromal cells on the modulation of costimulatory molecules of leukemic cells was not dependent on the source of stromal cells either allogeneic or autologous (data not shown). These data suggest that stCD40L and stroma induce leukemic cells phenotypic shift towards APC.
CD40 ligand-HBMS-stimulated BCP-ALL cells induce allogeneic T cells proliferation
To determine whether BCP-ALL cells cultured on HBMS ± stCD40L induced allogeneic T cells proliferation, we Figure 3 , BCP-ALL cells cultured on HBMS induced stronger allogeneic T cell proliferation than untreated BCP-ALL cells which had never been in contact with HBMS. The presence of stCD40L in the stroma supported-culture, further increased the APC capacity of leukemic cells (Figure 3, panels a and b) . In the results shown in panels c and d of Figure 3 , two additional controls were included: DC derived from normal donors as positive control of stimulator cells, and untreated BCP-ALL cells, from the same ALL patient, mixed with trypsinized HBMS and immediately selected without any further culture.
separated leukemic cells from HBMS by negative selection (see Materials and methods). As shown in
These data suggest that the contact with HBMS increases APC capacity of BCP-ALL cells and that the magnitude of proliferative response is enhanced by stCD40L.
CD40 ligand-stimulated BCP-ALL cells elicit IFN-␥ production by autologous BM T cells
In order to assess, in our hands, the sensitivity of the ELISPOT assay in the detection of low frequency IFN-␥ producing cells, we used MNC from HLA-A2.01 healthy donors with a recent positive anamnesis for influenza virus infection. In 5/7 tested cases we detected anti-influenza virus T cell precursors with a mean frequency of 1/8000 isolated T cells (range 1/15 000-Leukemia 1/3300), while in the remaining two cases, IFN-␥ producing cells were undetectable (data not shown).
In ALL experiments, T cells and BCP-ALL cells were purified by positive and negative selection, respectively. The % of CD3+ cells, before selection, was less than 5% in all analyzed cases. After purification, the number of recovered T cells ranged between 0.6 and 1.52 × 10 6 and the purity of CD3 + cells was Ͼ95%. The % (mean ± s.d.) of CD4 + and CD8 + cells, among purified CD3 + cells was 55 ± 15 and 38 ± 13, respectively. Negative selection of BCP-ALL cells was performed by using anti-fibroblasts, anti-CD4, anti-CD8-conjugated magnetic beads. In selected cases (UPN 21, UPN 22, UPN 23) , to further increase the efficacy of stroma cell depletion (monocytes and macrophages), anti-CD14-conjugated beads were added to the cocktail of antibodies. Depletion of unwanted cells was very efficient. As shown in Figure 4 for a representative case, the % of residual macrophages (CD14-positive cells) was 0.2% (UPN 21), 0.3% (UPN 22) and 0.2% (UPN 23). Fifty thousand purified T cell/well (U-bottom 96-well plate), were co-cultured with BCP-ALL cells for 72 h at 37°C and then tested for IFN-␥ production by a 24 h ELISPOT assay. The number of spots measured in 2 × 10 5 isolated T cells cultured with thawed ALL blasts, cultured with ALL blasts exposed to HBMS alone or cultured with ALL blasts exposed to HBMS in the presence of stCD40L, is shown in Table 3 . As controls, the spots measured by ALL blasts alone or by purified Expression of CD40, CD80 (B7-1) and CD86 (B7-2) molecules by BCP-ALL cells. The histograms show the flow cytometric analysis in two representative cases (patient UPN 17, top panels and patient UPN 18, bottom panels). BCP-ALL cells were stained with FITC-conjugated MoAbs within 1 h after thawing (left panels), after 48 h of stroma-supported culture (central panels) and after 48 h of stroma-supported culture in the presence of 0.5 g/ml of stCD40L (right panels). Blank areas represent fuorescence distribution of the antibodies and solid areas that of isotype-matched control antibodies.
Figure 2
Expression of MHC I, MHC II, CD54, CD58, CD10 and CD34 molecules by BCP-ALL cells. Bars represent mean fluorescence of intensity (MFI) of BCP-ALL cells measured by flow cytometry within 1 h after thawing (dark bars), after 48 h of stroma-supported culture (hatched bars) and after 48 h of stroma-supported culture in the presence of 0.5 g/ml of stCD40L (grey bars).
T cells alone are also indicated in Table 3 . In four cases (UPN  18, UPN 20, UPN 21, UPN 22) , the data clearly indicate the presence of leukemia-reactive T cell, well above the background values, when stroma CD40L-stimulated BCP-ALL were used as stimulators. The calculated frequencies of leukemiareactive T cells after background substraction are 1/900, 1/1560, 1/2150 and 1/1575 in patients UPN 18, UPN 20, UPN 21 and UPN 22, respectively.
We were concerned about the high background value of spots detected when ALL blast cells of UPN 20 were plated alone in the ELISPOT assay. Extensive analyses for the presence of residual T cells in the ALL blast cell preparation obtained after HBMS culture in the presence of stCD40L, revealed that it was in the same low range (0.2-0.3%) as observed in all remaining cases. T cells can belong to the ALL patient or to the HBMS donor. In the former case, T cells can be activated by allogeneic HBMS cells during the period of co-culture, whereas in the latter case by allogeneic stCD40L-stimulated BCP-ALL cells. Therefore we cannot rule out the Leukemia possibility that, despite very low frequencies, residual T cells in the enriched ALL cell population can be activated by an allogeneic stimulation and produce IFN-␥ accordingly.
Discussion
It has been shown that ALL cells are inefficient allogeneic APC and that CD40 cross-linking on ALL cells by CD40L can induce expression of B7 family members and convert nonimmunogenic ALL cells into competent APC, able to induce alloantigen-specific T cell proliferation 4 and generation of autologous anti-ALL-specific cytotoxic T cells. 5, 8 Our findings confirm and further extend the data reported by others 5 on the capacity of stCD40L to upregulate or to induce the expression of costimulatory molecules such as CD40, CD80 and CD86 in BCP-ALL cells. Also HBMS alone, although to a lesser extent, was able to induce modulation of CD40 and CD86, but not CD80, in a similar proportion of cases. This pheno- typic shift translates into an increased capacity of these cells to induce allogeneic proliferative response compared with either stroma-stimulated BCP-ALL blasts or untreated BCP-ALL blasts after thawing. CD40 expression by ALL cells seems to be an essential requisite for the interaction with CD40L and further upregulation of costimulatory molecules. Of note, as reported by others, 12, 13 only 30-45% of BCP-ALL patients express the CD40 antigen. In our series, 12 of 22 patients expressed CD40 when freshly isolated cells were analyzed, however, after a short-term culture on HBMS, 21 of 22 cases expressed CD40 (Table 2 ). This phenomenon seems not to be due to a direct cross-linking of CD40, because HBMS used in our experiments does not express CD154 (data not shown). Either direct cell-to-cell contact between ALL blasts and HBMS or stromasecreted soluble factors can support ALL blasts survival and proliferation. 11, 14 Phenotypic changes, induced by HBMS, on the expression of cell surface molecules such as CD13 and HLA-DR in BCP-ALL cells has been reported by Saito et al. 15 We demonstrated that short-term culture of BCP-ALL cells on HBMS can induce the phenotypic shift of BCP-ALL cells towards APC, but the mechanism involved in this phenomenon remains to be investigated.
We show that stCD40L-stimulated ALL cells are able to induce IFN-␥ production by autologous BM T cells isolated at the time of ALL onset, and that ELISPOT assay can be used to measure the frequency of these leukemia-reactive precursors, even after short-term culture with stCD40L-stimulated BCP-ALL cells. It is still unknown whether these IFN-␥ producing T cells can display cytotoxic properties. However, several studies have reported a linear correlation between the frequency of IFN-␥ producing lymphocytes and the level of specific cytotoxic activity. 16 Moreover, cytotoxic T cells from BM against autologous ALL blasts, have been generated by the co- Numbers depicted in the table represent the number of spots (IFN-␥ producing cells). The data shown in the Table refer to the total number of spots measured from 2 × 10 5 cells and therefore represent the total of four separated wells since 50 000 cells/well have been seeded. Intra-assay variability was not significant (mean ± s.d., data not shown). On the contrary, due to the low yeld of T cells after immunomagnetic purification (see Results), it was not possible to perform multiple tests on the same patient.
culture in the presence of CD40L and IL-2. 5 Demonstration of the existence of leukemia-reactive T cells in BM would be of great importance in order to understand the role of anti-tumor immune response.
Reactivation of memory cells by triggering a secondary immunologic response would induce a more rapid and protective reaction. [17] [18] [19] The detection of anti-tumor memory T cells in the BM has been recently demonstrated in patients with human breast carcinoma and melanoma. [20] [21] Tumor vaccination studies in mice revealed that BM is a major site for long-term persistence of tumor-specific memory T cells and of small numbers of dormant tumor cells that are kept under active host immune T cell control. 22, 23 Whether such antitumor memory resting T cells, measurable in the BM of BCP-ALL patients at diagnosis, survive the treatment, even with the currently used multiagent chemotherapy protocols, is still unknown. In this case, their activation after vaccination with stCD40L-stimulated ALL cells could potentially result in a clinical benefit. It could be argued that the reactivity against BCP-ALL cells, as measured by the detection of BM IFN-␥ producing T cells, was observed in most but not all ALL patients tested. Several hypotheses can be considered including the heterogeneity among BCP-ALL in their capacity to express tumor-specific antigens, as well as the presence of inhibitory activity in the BM microenviroment. Of note Cardoso et al 24 recently reported the existence of regulatory suppressive T cells in the BM which may facilitate failure of immune surveillance in ALL by secreting interleukin-10. Finally a T cell reactivity against BCP-ALL can be present in the BM at levels below the ELISPOT assay sensitivity.
Monitoring a CTL response in the context of a vaccine clinical trial, is essential in order to establish a direct correlation between clinical and immunological response. ELISPOT assay has performed well in the different setting of clinical vaccination. 20, 21, 25, 26 To our knowledge, this is the first report on the use of this assay to detect IFN-␥ producing BM T cells against CD40L-stimulated BCP-ALL cells. The role of HBMS and stCD40L to obtain functional APCs from BCP-ALL cells, together with the reproducibility of ELISPOT assay to measure the frequency of leukemia-reactive T cell, can provide the rationale to explore the use of BCP-ALL blasts in the context of a vaccine strategy.
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